OBIO ORCHESTRA BIOMED HOLDINGS INC

Orchestra BioMed to Present at Upcoming Investor Conferences

Orchestra BioMed to Present at Upcoming Investor Conferences

NEW HOPE, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at multiple upcoming investor conferences.

Details on the Company’s presence at these conferences are shown below.

Presentations

TD Cowen 45th Annual Healthcare Conference

Format: Corporate Presentation

Date: March 3, 2025

Time: 2:30 PM ET

Webcast:

Barclays 27th Annual Global Healthcare Conference

Format: Fireside Chat

Date: March 13, 2025

Time: 8:00 AM ET

Live audio webcasts of the TD Cowen presentation can be accessed through the Investors section of the Company’s website at . An archived replay of the webcast will be available on the Company’s website for 90 days following the live event.

The Company will also be hosting 1x1 meetings with investors at the B. Riley Securities Precision Oncology & RadioPharma Conference on February 28, 2025.

About Orchestra BioMed

Orchestra BioMed (Nasdaq: OBIO) is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Orchestra BioMed’s partnership-enabled business model focuses on forging strategic collaborations with leading medical device companies to drive successful global commercialization of products it develops. Orchestra BioMed’s lead product candidate is atrioventricular interval modulation (AVIM) therapy for the treatment of hypertension, a significant risk factor for death worldwide. Orchestra BioMed is also developing the Virtue® Sirolimus AngioInfusion™ Balloon (SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Orchestra BioMed has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for development and commercialization of AVIM therapy for the treatment of hypertension in pacemaker-indicated patients, and a strategic partnership with Terumo, a global leader in medical technology, for development and commercialization of Virtue SAB for the treatment of artery disease. For further information about Orchestra BioMed, please visit , and follow us on LinkedIn .

References to Websites and Social Media Platforms

References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release.

Investor Contact:

Jeremy Feffer

LifeSci Advisors

Media Contact:

Kelsey Kirk-Ellis

Orchestra BioMed

(484) 682-4892



EN
20/02/2025

Underlying

OBIOORCHESTRA BIOMED HOLDINGS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ORCHESTRA BIOMED HOLDINGS INC

 PRESS RELEASE
Free
OBIO ORCHESTRA BIOME...

Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data i...

Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction Echocardiographic data analysis demonstrated favorable impact of atrioventricular interval modulation (“AVIM”) therapy on MODERATO II study patients with diastolic dysfunction, a key component in the development of heart failure with preserved ejection fraction (“HFpEF”)Hypertension is the leading cause of diastolic dysfunction and the most common comorbidity in older patients indicated for a pacema...

August 14, 2025 1 EN
 PRESS RELEASE
Free
OBIO ORCHESTRA BIOME...

Orchestra BioMed Reports Second Quarter 2025 Financial Results and Hig...

Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates Secured over $111 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by over $71 million in committed capital from Medtronic and LigandAchieved multiple FDA regulatory milestones: Breakthrough Device Designation for AVIM therapy; approval for expanded BACKBEAT study enrollment criteria, and IDE approval for a U.S. pivotal Virtue SAB trial versus commercially available paclitaxel-coated balloon NEW...

August 12, 2025 1 EN
 PRESS RELEASE
Free
OBIO ORCHESTRA BIOME...

Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Piv...

Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility FDA-approved protocol update significantly expands patient eligibility criteria for the BACKBEAT global pivotal study (“BACKBEAT study”), resulting in an estimated more than 24-fold increase in the potentially eligible patient pool as compared to original study protocolExpanded eligibility criteria now include screening of any hypertensive patients who have received or are scheduled to receive a Medtronic Azure™ or Astra™ pacemaker, including device re...

August 8, 2025 1 EN
 PRESS RELEASE
Free
OBIO ORCHESTRA BIOME...

Orchestra BioMed Secures Over $111 Million in Proceeds and Committed C...

Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings $56.2 million in proceeds from completed public offering and concurrent private equity purchase by Medtronic and Ligand$55 million in proceeds and funding commitments from royalty-based, non-dilutive investments from Medtronic and LigandProceeds extend expected cash runway into the second half of 2027 and expected to fund completion of enrollment and follow up for the primary endpoint of the BACKBEAT study, as well as ...

August 5, 2025 1 EN
 PRESS RELEASE
Free
OBIO ORCHESTRA BIOME...

Orchestra BioMed Announces Pricing of $40 Million Public Offering

Orchestra BioMed Announces Pricing of $40 Million Public Offering NEW HOPE, Pa., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, announced today the pricing of an underwritten public offering of 9,413,637 shares of its common stock at a price to the public of $2.75 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 5,136,363 shares of its common stock at a price to t...

August 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch